公开(公告)号：US09730931B2

公开(公告)日：2017-08-15

申请号：US15221018

申请日：2016-07-27

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: A61K31/505 ,  C07D239/48 ,  C07D405/12 ,  C07D413/12 ,  A61K31/506 ,  C07C53/18 ,  C07D401/12 ,  C07D403/12 ,  A61K31/5377

CPC classification number: A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  C07C53/18 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

公开(公告)号：US09434697B2

公开(公告)日：2016-09-06

申请号：US15000659

申请日：2016-01-19

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: A61K31/505 ,  C07D239/48 ,  C07D401/12 ,  C07C53/18 ,  C07D403/12 ,  C07D413/12 ,  A61K31/506

CPC classification number: A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  C07C53/18 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Abstract translation: 本文提供了可用作FGFR4抑制剂的式I化合物，以及其用途的方法。

公开(公告)号：US20160130237A1

公开(公告)日：2016-05-12

申请号：US15000659

申请日：2016-01-19

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: C07D239/48 ,  C07D413/12 ,  C07D403/12 ,  C07D401/12 ,  C07C53/18

CPC classification number: A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  C07C53/18 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Abstract translation: 本文提供了可用作FGFR4抑制剂的式I化合物，以及其用途的方法。

公开(公告)号：US20240060068A1

公开(公告)日：2024-02-22

申请号：US18256428

申请日：2021-12-10

Applicant: Francis G. FANG ,  Dai-Shik KIM ,  Hyeong Wook CHOI ,  Yoshinori TAKAHASHI ,  Kenji KIKUTA ,  Hikaru KAWASHIMA ,  Toshiki KUROKAWA ,  Tamaki HOSHIKAWA ,  Mingde SHAN ,  John WANG ,  Eisai R&D Management Co., Ltd.

Inventor： Francis G. Fang ,  Dae-Shik Kim ,  Hyeong Wook Choi ,  Yoshinori Takahashi ,  Kenji Kikuta ,  Hikaru Kawashima ,  Wataru Itano ,  Toshiki Kurokawa ,  Tamaki Hoshikawa ,  Mingde SHAN ,  John Wang

IPC: C12N15/113 ,  C07H21/04

CPC classification number: C12N15/113 ,  C07H21/04 ,  C12N2310/341 ,  C12N2310/3233 ,  C12N2310/315

Abstract: Gapmers or pharmaceutically acceptable salt of the gapmers and methods of making the gapmers are provided. The gapmers include a gap region that contains deoxyribonucleosides linked to each other by phosphorothioate bonds, a 5′ wing region positioned at the 5′ end of the gap region that contains morpholino monomers linked to each other by phosphorodiamidate bonds, and a 3′ wing region positioned at the 3′ end of the gap region that contains morpholino monomers linked to each other by phosphorodiamidate bonds. Antisense oligonucleotides are also provided. These antisense oligonucleotides are useful in the preparation of gapmers for inhibition of Tau mRNA transcription.

公开(公告)号：US10537571B2

公开(公告)日：2020-01-21

申请号：US15627851

申请日：2017-06-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/5377

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

公开(公告)号：US20150329528A1

公开(公告)日：2015-11-19

申请号：US14710687

申请日：2015-05-13

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Gregg F. Keaney ,  John Wang ,  Baudouin Gerard ,  Kenzo Arai ,  Xiang Liu ,  Guo Zhu Zheng ,  Kazunobu Kira ,  Parcharee Tivitmahaisoon ,  Sudeep Prajapati ,  Nicholas C. Gearhart ,  Yoshihiko Kotake ,  Satoshi Nagao ,  Regina Mikie Kanada Sonobe ,  Masayuki Miyano ,  Norio Murai

IPC: C07D405/14 ,  C07D405/06

CPC classification number: C07D405/14 ,  C07D405/06

Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Abstract translation: 本发明提供新颖的扁桃苷内酰吡啶化合物，含有这些化合物的药物组合物，以及使用该化合物作为治疗剂的方法。 这些化合物可用于治疗癌症，特别是癌症，其中靶向剪接体的试剂和其中的突变已知是有用的。